We are live on ! Find out more

BBNX

Beta Bionics

BBNX

Market cap $870M

19.33 USD

-0.09

0.46%

At close Updated Sep 8, 4:00 PM EDT

Pre-market

After hours

19.33

0.00

0%

1 day

-0.46%

5 days

-2.13%

1 month

17.87%

3 months

39.37%

6 months

77.83%

Year to date

-33.91%

1 year

-16.43%

5 years

-18.2%

10 years

-18.2%

About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Employees: 423

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 2.9%

Neutral 94.1%

Negative 2.9%

BBNX INVESTOR ALERT: Securities Class Action Filed Against Beta Bionics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)---- $BBNX #ClassActionLawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or i.

BBNX INVESTOR ALERT: Securities Class Action Filed Against Beta Bionics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a shareholder-rights law firm, announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).

BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline

BBNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

NEW YORK--(BUSINESS WIRE)---- $BBNX #BBNX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Th.

BBNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Beta Bionics, Inc. (BBNX)

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 to February 24, 2026, inclusive (the “Class Period”).

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Beta Bionics, Inc. (BBNX)

BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period").

BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

BETA BIONICS, INC. (BBNX) INVESTOR ALERT Investors With Large Losses in Beta Bionics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) between June 30, 2025 and February 24, 2026, inclusive.

BETA BIONICS, INC. (BBNX) INVESTOR ALERT Investors With Large Losses in Beta Bionics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Perio.

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

BBNX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Beta Bionics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

ATLANTA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics”) (NASDAQ: BBNX). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding Beta Bionics's iLet Bionic Pancreas insulin pump and the device's safety.

BBNX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Beta Bionics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026. Beta Bionics describes itself as a “commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations:.

Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

LOS ANGELES, Sept. 8, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period").

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

See News Rankings

Price charts implemented using Lightweight Charts™